Use of implantable cardioverter defibrillators in the New Zealand context from 2000 to 2007

New Zealand Medical Journal

Volumn 123, Issue 1309, 2010, Pages 76-85

  Larsen, Peter D ^a   De Silva, Praveen ^a   Harding, Scott A ^b   Woodcock, Ellen ^a   Lever, Nigel A ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WELLINGTON HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATOR; FEMALE; HEART PACING; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD; MORTALITY; NEW ZEALAND; PRESCHOOL CHILD; PRIMARY PREVENTION; SCHOOL CHILD; SECONDARY PREVENTION; SUDDEN DEATH; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART DISEASES; HUMANS; INFANT; MALE; MEDICAL AUDIT; MIDDLE AGED; NEW ZEALAND; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; YOUNG ADULT;

EID: 77149145245     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cannom DS, Prystowsky EN. The evolution of the implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004;27(3):419-31.
2. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997;337(22):1576-83.
3. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341(25):1882-90.
4. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335(26):1933-40.
5. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83.
6. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37.
7. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm 2005;2(5):497-504.
8. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007;28(3):334-44.
9. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51(21):e1-62.
10. Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace 2007;9(10):959-98.
11. Chase D, Roderick PJ, Burnley H, et al. Is there unmet need for implantable cardioverter defibrillators? Findings from a post-mortem series of sudden cardiac death. Europace 2008;10(6):741-6.
12. Plummer CJ, John Irving R, McComb JM. The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district. Europace 2005;7(3):266-72.
13. Scott PA, Gorman S, Andrews NP, et al. Estimation of the requirement for implantable cardioverter defibrillators for the primary prevention of sudden cardiac death post-myocardial infarction based on UK national guidelines (2006). Europace 2008;10(4):453-7.
14. Population estimates and projectionsStatistics NZ. 2008.
15. Ector H, Vardas P. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. Eur Heart J 2007;9 Suppl 1:I44-I49.
16. Proclemer A, Ghidina M, Cicuttini G, et al. Impact of the main implantable cardioverter-defibrillator trials for primary and secondary prevention in Italy: a survey of the national activity during the years 2001-2004. Pacing Clin Electrophysiol 2006;29 Suppl 2:S20-8.
17. Peinado R, Torrecilla EG, Ormaetxe J, Alvarez M. [Spanish registry of implantable cardioverter defibrillator. Second official report of the Spanish Society of Cardiology Working Group on Implantable Cardioverter Defibrillators (2005)]. Rev Esp Cardiol 2006;59(12):1292-302.
18. The Danish Pacemaker and ICD Registry: www.pacemaker.dk, 2006.
19. Mond HG, Whitlock RM. The Australian and New Zealand cardiac pacing and implantable cardioverter-defibrillator survey: calendar year 2005. Heart Lung Circ 2008;17(2):85-9.
20. OECD. OECD Heatlh Data 2008: OECD, 2008.
21. Grimm W, Stula A, Sharkova J, et al. Outcomes of elderly recipients of implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2007;30 Suppl 1:S134-8.
22. Gold MR, Shih HT, Herre J ,et al. Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol 2007;100(2):243-6.
23. Pires LA, Johnson KM. Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? J Cardiovasc Electrophysiol 2006;17(2):140-5.
24. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001;104(7):796-801.
25. Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006;48(2):330-9.
26. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;52(7):541-50.
27. Soundarraj D, Thakur RK, Gardiner JC, et al. Inappropriate ICD therapy: does device configuration make a difference. Pacing Clin Electrophysiol 2006;29(8):810-5.
28. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51(14):1357-65.